Differential modulation of dopamine D 1 -receptor binding and mRNA expression in the basal ganglia by the D 1 -receptor antagonist, SCH-23390
Dopamine D 1 -receptor binding in the basal ganglia is differentially regulated by subtype nonspecific dopamine antagonists such as the antipsychotic, Fluphenazine. The purpose of the present study was to determine the relative contributions of D 1 and D 2 receptor systems in the regulation of basal...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | JOUR |
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_08874476_v30_n1_p38_Yu |
| Aporte de: |
| Sumario: | Dopamine D 1 -receptor binding in the basal ganglia is differentially regulated by subtype nonspecific dopamine antagonists such as the antipsychotic, Fluphenazine. The purpose of the present study was to determine the relative contributions of D 1 and D 2 receptor systems in the regulation of basal ganglia D 1 -receptor binding. Rats were injected twice daily for 21 days with saline, the D 1 -receptor antagonist, SCH-23390, the D 2 -receptor antagonist, Raclopride, or both SCH-23390 and Raclopride. Dopamine D 1 -receptor levels (as indicated by [ 125 I]SCH-23982 binding) and mRNA expression were measured using receptor autoradiographic and in situ hybridization histochemical techniques. [ 125 I]NCQ-298 binding to D 2 - receptors was also measured as a positive control for the effects of Raclopride. SCH-23390 administration independently increased [ 125 I]SCH- 23982 binding in a region-dependent manner with the greatest increases occurring in the entopeduncular nucleus. SCH-23390 also increased D 1 - receptor mRNA expression in specific striatal subregions suggesting that increases in binding were related to changes in receptor synthesis. In addition, Raclopride independently enhanced D 2 binding with comparable increases observed in extrastriatal regions and increases of a lesser magnitude in the striatum. These data show that the modulation of basal ganglia D 1 -receptor binding observed in animals treated with nonselective antagonists is due primarily to the blockade of D 1 -receptors. The differential enhancement in basal ganglia D 1 binding observed after D 1 - receptor blockade may be due to anatomical or phenotypic heterogeneity within the population of striatal D 1 -receptor synthesizing neurons. Similarly, the differential enhancement in striatal and extrastriatal D 2 -receptor binding may be due to differences in the regulation of striatal and extrastriatal D 2 -receptor synthesizing neurons. |
|---|